StreetAlpha.app
Home › Stocks › COYA

Coya Therapeutics, Inc. (COYA)

$3.02
▲ +0.67%
LAST CLOSE · NOV 17

Coya Therapeutics develops biologic treatments that aim to restore regulatory T cell function for patients with serious diseases. It last closed at $3.02 on Nov 17, up 0.67% on the day. The average 12-month price target from 2 analysts is $14.00 (+363.6% from the last close), with a high of $16.00 and a low of $12.00.

AI Auto Pilots
Is COYA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$4.7M
+17.6% vs a year ago
Net income
−$30.2M
−643.5% margin
EPS (diluted)
−$1.39
Operating margin
−675.3%
−$31.7M operating income
Valuation
Market cap
$70.8M
23.5M shares
P/E
–
No P/E while losing money
Price to sales
15.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$35.8M
At Sep 30
Shareholder equity
$33.6M
Shares outstanding
23.5M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $0$0FY2022FY2023: $6.0M$6.0MFY2023FY2024: $3.6M$3.6MFY2024FY2025: $7.9M$7.9MFY2025

From COYA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated COYA in the past 90 days, not enough for a consensus
Average 12-month target
$14.00
▲ 363.6% upside

Based on 2 analysts who set a price target on COYA in the past 90 days. The average target is $14.00, with a high of $16.00 and a low of $12.00, compared with the last close of $3.02.

Low $12.00Avg $14.00High $16.00
Blue marker: last close $3.02
Highest target$16.00
Average target$14.00
Lowest target$12.00
Latest rating changes
BTIGReiterated
Sep 15Buy$16
Roth CapitalReiterated
Aug 24Buy$12
Chardan CapitalMaintained
Aug 12Buy$14
Roth CapitalInitiated
Jun 5Buy$12
DateFirmActionRatingPrice target
Sep 15BTIGReiteratedBuy$16
Aug 24Roth CapitalReiteratedBuy$12
Aug 12Chardan CapitalMaintainedBuy$14
Jun 5Roth CapitalInitiatedBuy$12
Loading…

Technical Analysis

COYA · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 15% below its 20 day and 40% below its 50 day average. It is 51% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 33), near oversold. The nearest support is the Pivot at $3.00, and the nearest resistance the Pivot R1 at $3.08.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 9.9%/day
Key levels
$6.6252 week high+119.2%
$4.55200 day average+50.7%
$4.51100 day average+49.3%
$4.2350 day average+40.1%
$3.4720 day average+14.9%
$3.47Swing high (Nov 10)+14.9%
$3.08Pivot R1+2.0%
$3.02Last close
$3.00Pivot−0.7%
$2.95Pivot S1−2.3%
$2.7252 week low−9.9%
$2.72Swing low (Nov 5)−9.9%
Indicators
RSI (14)33.05Weak, oversold below 30Neutral
MACD-0.36Below its signal lineBearish
Stochastic21.7Middle of its rangeNeutral
ADX (14)28.4Trending down
Williams %R-79.7Oversold below −80, overbought above −20Neutral
CCI (20)-76.5Oversold below −100, overbought above 100Neutral
Rate of change−4.4%Change over 10 sessionsBearish
ATR (14)$0.30Typical daily range, 9.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for COYA

What happened before

See how COYA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow COYA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How COYA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in COYA in the last 90 days.

Loading…

See today’s whale options flow across the market →

COYA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ▼15 buying vs 23 selling
  • ▼Held by funds -2.1 pts
  • ▼Funds holding -2
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding5254−3.7%
In funds' top 1000–
Held by funds31.5%33.5%−2.1 pts
New / increased6 / 95 / 14−21.1%
Reduced / sold out14 / 916 / 70.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See COYA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether COYA is in one of them and how their past COYA trades turned out.

COYA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered COYA in an article yet. Here's the latest on the wider market.

About Coya Therapeutics

Coya Therapeutics is a biotechnology company based in Houston, Texas. It is developing treatments that aim to restore the function of regulatory T cells, immune cells that help keep inflammation in check. Its lead candidate, COYA 302, is in clinical testing for amyotrophic lateral sclerosis and is also planned for frontotemporal dementia. The company's therapies are intended for patients with neurodegenerative, autoimmune and metabolic diseases.

Headquarters
Houston, TX